FDA approves giredestrant for breast cancer
-
By
-
Mouj Hijazi
-
November 17, 2026
-
2 min
Clinical Scorecard: FDA approves giredestrant for breast cancer
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: FDA approves giredestrant for breast cancer |
| Key Mechanisms | Giredestrant is an oral estrogen receptor antagonist that blocks estrogen signaling and promotes estrogen receptor degradation. |
| Target Population | Patients or participants described in the source article. |
| Care Setting | Care setting described in the source article. |
Key Highlights
- FDA approval covers giredestrant with everolimus for eligible adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
- FoundationOne Liquid CDx was authorized as a companion diagnostic to identify eligible patients with ESR1 mutations.
- In the phase 3 evERA trial, median progression-free survival among patients with ESR1-mutated tumors was 10 months with giredestrant plus everolimus versus 5.5 months with comparator endocrine therapy plus everolimus.
- Objective response rates in the ESR1-mutated subgroup were 27% and 14%, respectively; overall survival data were immature at the time of the PFS analysis.
- Common adverse reactions included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea.
Guideline-Based Recommendations
Diagnosis
- Use FoundationOne Liquid CDx as an authorized companion diagnostic to identify eligible patients with ESR1 mutations.
Management
- The recommended giredestrant dose is 30 mg orally once daily, with or without food, in combination with everolimus 10 mg daily.
- Continue treatment until disease progression or unacceptable toxicity.
- Avoid strong CYP3A inhibitors and inducers.
Monitoring & Follow-up
- Monitor heart rate more frequently in patients with preexisting bradycardia or taking medications that slow heart rate.
Risks
- The prescribing information includes warnings for bradycardia and embryo-fetal toxicity.
- Bradycardia occurred in 3.8% of patients receiving the combination in evERA; all cases were asymptomatic.
- Common adverse reactions reported in at least 20% of patients included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea.
Patient & Prescribing Data
Adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease recurred during or after endocrine-based adjuvant therapy or progressed on at least one endocrine-based regimen in the metastatic setting.
Giredestrant 30 mg orally once daily, with or without food, is given with everolimus 10 mg daily until disease progression or unacceptable toxicity. Avoid strong CYP3A inhibitors and inducers.
Clinical Best Practices
- Confirm ESR1 mutation status using the authorized companion diagnostic when assessing eligibility.
- Review heart rate and medications that slow heart rate; increase heart rate monitoring for patients with preexisting bradycardia or relevant concomitant medications.
- Review the prescribing information warnings for embryo-fetal toxicity and bradycardia, and avoid strong CYP3A inhibitors and inducers.
Related Resources & Content
Based on findings from:
FDA approves giredestrant for breast cancer
Mouj Hijazi. MDSpire News, 2026.
https://news.mdspire.com/obgyn/articles/fda-approves-giredestrant-for-breast-cancer/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.